earnings
confidence high
sentiment positive
materiality 0.70
Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84
AMGEN INC
2025-FY EPS reported
$14.23
revenue$36,751,000,000
- Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.
- GAAP EPS $2.45 Q4 (+111%), full year $14.23 (+88%); non-GAAP EPS full year $21.84 (+10%).
- Recorded $1.2B Otezla intangible impairment due to IRA Medicare price setting.
- Free cash flow $8.1B full year vs $10.4B prior, down on working capital timing.
- 18 products achieved record full-year sales; 14 exceeded $1B in annual sales.